Ireland
--:--IST
Latest
Clinical Trials in France / NCT06033183
Recruiting Not applicable

Integrative Molecular Analysis of Individual Radiosensitivity in Pediatric Oncology

NCT06033183 · tracked via the Priya Life Science France tracker
Sponsor
Neolys
Phase
Not applicable
Started
2023-12-02
Last updated
2024-11-22

Condition(s) studied

RadiosensitivityPediatric CancerRadiation Toxicity

Investigational drug(s) / intervention(s)

Blood sample →

Blood sample: Blood sample collection : 2 X 5 ml

Study summary

Analysis of the individual radiosensitivity in pediatric oncology

Eligibility

Sex
ALL
Min age
3 Years
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: * Minor patient treated for a brain tumor, Ewing tumor, malignant mesenchymal tumor, neuroblastoma, nephroblastoma, Hodgkin's lymphoma treated with radiotherapy (+/- chemotherapy) for curative purposes. * Children or adolescents \> 3 years old and \< 18 years old * Patient with an indication for radiotherapy as part of the primary tumor local control strategy * Theoretical indication for radiotherapy in standard fractionation (1.8 Gy to 2.2 Gy / fraction: 5 fr/week) whatever the technique and the particle used * Patient affiliated with a social security scheme * Patient and/or parents or holders of parental authority having dated and signed an informed consent Exclusion criteria: * Patients with contraindications to blood sampling * Patients with contraindications to radiotherapy * Palliative radiotherapy * Patient with previous RT treatment in the same area (re-irradiation) * Patient with an indication of hypofractionated RT * Patient follow-up not possible * Persons deprived of liberty or under guardianship (including curatorship) Exclusion Criteria: \-

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Centre François Baclesse Caen France Recruiting
Centre Oscar Lambret Lille France Not Yet Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06033183 on ClinicalTrials.gov ↗ ← All trials in France